RenovoRxRNXT
Recorded

RenovoRx 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration27 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon. I will be your conference call operator today. Please note that today's call is being recorded, and all participants other than management are in listen-only mode. There will be a Q&A session following management's presentation. I will now turn the call over to Stephanie Carrington, Managing Director of ICR Healthcare. Please go ahead. Thank you, operator.

Stephanie CarringtonManaging Director

Good afternoon and welcome, everyone, to the RenovoRx third quarter 2026 earnings results conference call. I am joined today by members of the leadership team, including Shaun Bagai, Chief Executive Officer, Dr. Ramtin Agah, Chief Medical Officer, Executive Chair, and Founder, and Mark Voll, Chief Financial Officer. Before we begin, I'd like to remind everyone that statements made during today's call contain or may contain forward-looking statements covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and applicable federal securities laws. These statements, including statements regarding RenovoRx's commercial activities and strategies, clinical plans, and expectations of financial or operational performance, including projected revenues, projected active commercial cancer centers, and timing for completion and data readout of the company's TIGeR-PaC trial, are based on management's current plans and assumptions, and actual results may differ materially.

Stephanie CarringtonManaging Director

Please refer to our filings with the SEC, including our Form 10-Q for the quarter ended September 30, 2026, for detailed discussions of the risks and uncertainties facing RenovoRx. With that, I'd like to turn over the call to our Chief Executive Officer, Shaun Bagai.

Shaun BagaiCEO

Thank you, Stephanie, and good afternoon, everyone. The third quarter 2026 was a milestone quarter for RenovoRx as we continued to deliver on all three of our core priorities. First, for the first time in our history, quarterly revenue exceeded the million-dollar threshold. Second, we grew our customer base of active commercial cancer centers, expanded our sales pipeline, and completed the build-out of our sales organization. Third, we advanced the expansion for our TAMP platform and RenovoCath device beyond locally advanced pancreatic cancer. In sum, we continue to deliver on multiple fronts. During the third quarter, RenovoRx generated record revenue of approximately $1.1 million, our strongest quarterly performance to date, increasing approximately 17% sequentially and nearly a 300% increase, or more than fourfold higher year-over-year.

Shaun BagaiCEO

Revenue for the first nine months of 2026 was approximately $2.5 million, more than double our full-year 2025 revenue of $1.1 million. This is a direct, measurable result of the commercial model we have described. Every new commercial cancer center we activate drives more procedures and revenue, accelerating growth. Driving much of our growth is our fully staffed sales team that continues to gain traction and accelerate customer engagement and adoption of TAMP. The sales team, comprised of a vice president of sales and market development and five regional market development managers, is strategically deployed to cover major U.S. cancer centers. Our focused and regionally deployed sales team is sufficiently sized to address the market and effectively penetrate cancer centers that treat solid tumors, such as pancreatic cancer. For example, approximately 98% of pancreatic cancer diagnoses occur within roughly 200 cancer centers nationwide.

Shaun BagaiCEO

When you analyze these centers further, the market concentration becomes even more pronounced. The top 25 centers account for about 40% of all U.S. pancreatic cancer diagnoses, and the top 100 centers represent more than 75% of total diagnoses. Given this distribution, a focused and regionally deployed team of five field representatives is appropriately sized to effectively access and support these centers. Let's refresh on the predictors of future revenue growth. The leading indicator of continued revenue growth for RenovoCath in the coming quarters, and the metric I would encourage investors to continue to watch most closely, is new account activations. Our activated commercial cancer center customers to date have been a source of recurring repeat demand, so the pace at which we activate accounts is what gives us confidence.

Shaun BagaiCEO

We ended the third quarter 2026 with 26 active commercial cancer center customers, compared to 21 at the end of second quarter 2026. We remain confident in our ability to meet our year-end 2026 target of 36 active commercial cancer center customers as we continue to activate centers in the commercial funnel and convert sites from our fully enrolled phase III TIGeR-PaC trial to active centers. Our customer pipeline beyond these active sites is robust and expanding. In addition to the 26 active centers today, we have more than 40 additional centers in various stages of evaluation, approval, or activation in our commercial funnel. Combined, this represents a total commercial funnel of more than 65 centers. Another key metric of commercial success is repeat orders.

Shaun BagaiCEO

We continue to see strong repeat ordering from the majority of our existing customers, which we believe signals physician satisfaction and confidence in RenovoCath as a drug delivery option in interventional oncology. RenovoCath adoption is increasingly driven by physicians sharing firsthand experience with the device. This sharing continues to generate evidence and practical insights shared through peer-reviewed publications, medical meetings, and clinician-to-clinician discussions. Because interventional surgical and gastrointestinal oncology specialists work closely together, a positive RenovoCath experience at one center can accelerate adoption at the next. Physicians' confidence in our technology is reinforced by the growing body of clinical evidence that supports the use of TAMP and RenovoCath, which includes two recently peer-reviewed publications. Ramtin will walk you through both studies in greater detail. As we continue to commercialize, feedback from physicians tells us that the clinical need we are addressing is consistent across active centers.

Shaun BagaiCEO

TAMP is most often used in patients whose tumors cannot be surgically removed and whose disease has not sufficiently responded to systemic chemotherapy to allow for surgery. We therefore have a clear picture of where and how TAMP is being utilized. I want to take a moment to touch on the current overall pancreatic cancer market and how we believe this benefits us. There has been significant industry attention recently on new therapies for pancreatic cancer, and we believe those developments may represent a meaningful opportunity for RenovoRx. Given that RenovoCath is a device designed to offer the potential to deliver treatments more optimally, we see breakthroughs in pancreatic cancer therapy as complementary and as an important potential tailwind for our business. I want to remind everyone that our TAMP platform, enabled by RenovoCath, is a collaborative, localized drug delivery platform with two ways emerging therapies can strengthen our opportunity.

Shaun BagaiCEO

First, for standard of care therapeutics, our platform can deliver established drugs locally near to the tumor site, sequentially to or concurrently with novel therapies, creating the potential for improved patient outcomes, concentrating therapy where it is needed, and providing more treatment options for patients with difficult-to-treat disease. Second, as new drugs come to market, the range of therapies that can be delivered locally via our RenovoCath device may expand. In both cases, our view is that novel, improved therapies make the potential for our targeted drug delivery platform even more valuable. Turning to potential market expansion, we announced in August that a physician at one of our active centers used RenovoCath to deliver chemotherapy to a patient with sarcoma. This marks the first commercial use beyond locally advanced pancreatic cancer, or LAPC, and real-world potential for localized delivery of chemotherapy in other solid tumors.

Shaun BagaiCEO

Additionally, the University of Vermont treated its first patient in late October in an investigator-initiated trial, or IIT, evaluating TAMP before surgery in patients with planned surgical resection for the first time in the neoadjuvant setting. IITs are capital-efficient and enable independent investigators to generate safety and tolerability data of new applications for TAMP. Ramtin Agah will go into more detail about physician-driven expansions beyond LAPC, an important and encouraging element as we look toward the potential for broader adoption of RenovoCath. We have also continued to strengthen our intellectual property position. The U.S. Patent and Trademark Office issued a notice of allowance in Q3 for a new patent covering our RenovoCath dual-occlusion catheter system, bringing our portfolio to 10 issued or allowed U.S. patents, 10 issued OUS patents, six pending U.S. cases, seven pending OUS cases, and two pending PCT applications.

Shaun BagaiCEO

In closing, I could not be prouder of our team for their execution and hard work. The third quarter was a record quarter as we exceeded the million-dollar threshold. Active commercial cancer centers grew from 21 to 26, and our total commercial funnel now surpasses 65 centers. Moreover, in October, the first patient was treated in an IIT evaluating TAMP before surgery in patients with planned surgical resection in the neoadjuvant setting. With our sales organization now fully staffed and the activity of the team still ramping, we are well-positioned to continue executing as we close out 2026. With the commercial progress we continue to see to date, we are maintaining our full-year 2026 revenue guidance of $3.75 million-$4.25 million. I will now turn the call over to our Chief Medical Officer, Executive Chair, and Founder, Dr. Ramtin Agah.

Ramtin AgahCMO, Executive Chair, and Founder

Before turning to the broader opportunity, I want to briefly revisit the science underpinning our potential TAMP platform. TAMP is designed to deliver therapeutic agents, including chemotherapy and potentially other therapies, through the arterial wall near the tumor, concentrating treatment at the target site while potentially reducing toxicity compared with systemic intravenous therapy. For patients facing both solid tumors and burdensome treatment side effects, the distinction can be meaningful. Cancer treatment has traditionally relied on three primary approaches: surgery, radiation, and systemic chemotherapy. We believe TAMP, enabled by RenovoCath, can augment these approaches. RenovoRx reached a major company milestone at the end of August. We completed enrollment in our phase III TIGeR-PaC trial for locally advanced pancreatic cancer. This achievement advances our lead clinical program. TIGeR-PaC is evaluating whether our patented targeted delivery of gemcitabine can improve survival, safety, and tolerability compared with standard systemic intravenous gemcitabine plus Abraxane.

Ramtin AgahCMO, Executive Chair, and Founder

We expect initial top-line data in the second half of 2027 and expect the data readout to support and potentially expand current clinical adoption of TAMP by providing more rigorous evidence on tolerability and reduced side effects. The trial may also show whether TAMP can improve survival in this setting. Additionally, in August, we announced pharmacokinetic and pharmacodynamic data from a sub-study of the TIGeR-PaC trial in the Journal of Cancer Chemotherapy and Pharmacology. The findings from this PK/PD study provide additional meaningful mechanistic support for our TAMP platform's targeted drug delivery approach. In short, data from this randomized study demonstrated significant drug uptake directly near the tumor site, with reduced systemic drug levels. These results provide direct pharmacokinetic evidence supporting TAMP's potential to deliver chemotherapy more selectively to the tumor while limiting systemic exposures.

Ramtin AgahCMO, Executive Chair, and Founder

These findings strengthen TAMP, enabled by our RenovoCath device, as a differentiated approach to potentially improve the therapeutic index of chemotherapy in patients with locally advanced pancreatic cancer. In October, researchers at Hackensack Meridian Health Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. In it, physicians shared their own experience using TAMP to treat patients diagnosed with locally advanced pancreatic cancer whose tumors were not surgically removable due to significant complex blood vessel involvement, despite receiving extensive prior therapy. We are encouraged that physicians are independently documenting and sharing their experiences with TAMP and its potential to provide clinical benefit for patients. Independent peer-reviewed publications such as this add to the growing body of clinical evidence supporting TAMP, enabled by RenovoCath.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day